BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 28059785)

  • 21. Magnesium Reduces Blood-Brain Barrier Permeability and Regulates Amyloid-β Transcytosis.
    Zhu D; Su Y; Fu B; Xu H
    Mol Neurobiol; 2018 Sep; 55(9):7118-7131. PubMed ID: 29383689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of Hit Compounds Identified from High-throughput Screening for their Effect on Blood-brain Barrier Integrity and Amyloid-β Clearance: In Vitro and In Vivo Studies.
    Elfakhri KH; Duong QV; Langley C; Depaula A; Mousa YM; Lebeouf T; Cain C; Kaddoumi A
    Neuroscience; 2018 May; 379():269-280. PubMed ID: 29596966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LRP1 mediates bidirectional transcytosis of amyloid-β across the blood-brain barrier.
    Pflanzner T; Janko MC; André-Dohmen B; Reuss S; Weggen S; Roebroek AJ; Kuhlmann CR; Pietrzik CU
    Neurobiol Aging; 2011 Dec; 32(12):2323.e1-11. PubMed ID: 20630619
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amylin receptor ligands reduce the pathological cascade of Alzheimer's disease.
    Zhu H; Xue X; Wang E; Wallack M; Na H; Hooker JM; Kowall N; Tao Q; Stein TD; Wolozin B; Qiu WQ
    Neuropharmacology; 2017 Jun; 119():170-181. PubMed ID: 28363773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transthyretin stability is critical in assisting beta amyloid clearance- Relevance of transthyretin stabilization in Alzheimer's disease.
    Alemi M; Silva SC; Santana I; Cardoso I
    CNS Neurosci Ther; 2017 Jul; 23(7):605-619. PubMed ID: 28570028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Actions of β-amyloid protein on human neurons are expressed through the amylin receptor.
    Jhamandas JH; Li Z; Westaway D; Yang J; Jassar S; MacTavish D
    Am J Pathol; 2011 Jan; 178(1):140-9. PubMed ID: 21224052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease.
    Deane R; Bell RD; Sagare A; Zlokovic BV
    CNS Neurol Disord Drug Targets; 2009 Mar; 8(1):16-30. PubMed ID: 19275634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic cerebral hypoperfusion alters amyloid-β transport related proteins in the cortical blood vessels of Alzheimer's disease model mouse.
    Shang J; Yamashita T; Tian F; Li X; Liu X; Shi X; Nakano Y; Tsunoda K; Nomura E; Sasaki R; Tadokoro K; Sato K; Takemoto M; Hishikawa N; Ohta Y; Abe K
    Brain Res; 2019 Nov; 1723():146379. PubMed ID: 31415766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipopolysaccharide alters the blood-brain barrier transport of amyloid beta protein: a mechanism for inflammation in the progression of Alzheimer's disease.
    Jaeger LB; Dohgu S; Sultana R; Lynch JL; Owen JB; Erickson MA; Shah GN; Price TO; Fleegal-Demotta MA; Butterfield DA; Banks WA
    Brain Behav Immun; 2009 May; 23(4):507-17. PubMed ID: 19486646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro discrimination of the role of LRP1 at the BBB cellular level: focus on brain capillary endothelial cells and brain pericytes.
    Candela P; Saint-Pol J; Kuntz M; Boucau MC; Lamartiniere Y; Gosselet F; Fenart L
    Brain Res; 2015 Jan; 1594():15-26. PubMed ID: 25451130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of choroid plexus in IVIG-induced beta-amyloid clearance.
    Gu H; Zhong Z; Jiang W; Du E; Dodel R; Farlow MR; Zheng W; Du Y
    Neuroscience; 2014 Jun; 270():168-176. PubMed ID: 24747018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ANKS1A regulates LDL receptor-related protein 1 (LRP1)-mediated cerebrovascular clearance in brain endothelial cells.
    Lee J; Lee H; Lee H; Shin M; Shin MG; Seo J; Lee EJ; Park SA; Park S
    Nat Commun; 2023 Dec; 14(1):8463. PubMed ID: 38123547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ketone Bodies Promote Amyloid-β
    Versele R; Corsi M; Fuso A; Sevin E; Businaro R; Gosselet F; Fenart L; Candela P
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32023814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Astaxanthin exerts protective effects similar to bexarotene in Alzheimer's disease by modulating amyloid-beta and cholesterol homeostasis in blood-brain barrier endothelial cells.
    Fanaee-Danesh E; Gali CC; Tadic J; Zandl-Lang M; Carmen Kober A; Agujetas VR; de Dios C; Tam-Amersdorfer C; Stracke A; Albrecher NM; Manavalan APC; Reiter M; Sun Y; Colell A; Madeo F; Malle E; Panzenboeck U
    Biochim Biophys Acta Mol Basis Dis; 2019 Sep; 1865(9):2224-2245. PubMed ID: 31055081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amylin and its G-protein-coupled receptor: A probable pathological process and drug target for Alzheimer's disease.
    Qiu WQ
    Neuroscience; 2017 Jul; 356():44-51. PubMed ID: 28528968
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heparan sulphate proteoglycan and the low-density lipoprotein receptor-related protein 1 constitute major pathways for neuronal amyloid-beta uptake.
    Kanekiyo T; Zhang J; Liu Q; Liu CC; Zhang L; Bu G
    J Neurosci; 2011 Feb; 31(5):1644-51. PubMed ID: 21289173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Copper Exposure Perturbs Brain Inflammatory Responses and Impairs Clearance of Amyloid-Beta.
    Kitazawa M; Hsu HW; Medeiros R
    Toxicol Sci; 2016 Jul; 152(1):194-204. PubMed ID: 27122238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mixed oligomers and monomeric amyloid-β disrupts endothelial cells integrity and reduces monomeric amyloid-β transport across hCMEC/D3 cell line as an in vitro blood-brain barrier model.
    Qosa H; LeVine H; Keller JN; Kaddoumi A
    Biochim Biophys Acta; 2014 Sep; 1842(9):1806-15. PubMed ID: 24997450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain.
    Deane R; Sagare A; Hamm K; Parisi M; Lane S; Finn MB; Holtzman DM; Zlokovic BV
    J Clin Invest; 2008 Dec; 118(12):4002-13. PubMed ID: 19033669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduction of brain beta-amyloid (Abeta) by fluvastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, through increase in degradation of amyloid precursor protein C-terminal fragments (APP-CTFs) and Abeta clearance.
    Shinohara M; Sato N; Kurinami H; Takeuchi D; Takeda S; Shimamura M; Yamashita T; Uchiyama Y; Rakugi H; Morishita R
    J Biol Chem; 2010 Jul; 285(29):22091-102. PubMed ID: 20472556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.